Credit Suisse Group AG reiterated their outperform rating on shares of Shire PLC (LON:SHP) in a report issued on Friday. The firm currently has a GBX 5,200 ($67.88) price objective on the biopharmaceutical company’s stock.

A number of other research analysts have also recently weighed in on the stock. Shore Capital restated a buy rating on shares of Shire PLC in a report on Thursday. JPMorgan Chase & Co. restated an overweight rating on shares of Shire PLC in a report on Monday, October 3rd. BNP Paribas restated an outperform rating and issued a GBX 5,900 ($77.01) price objective on shares of Shire PLC in a report on Friday, September 30th. Goldman Sachs Group Inc. restated a conviction-buy rating and issued a GBX 6,300 ($82.23) price objective on shares of Shire PLC in a report on Thursday, September 29th. Finally, HSBC dropped their price objective on shares of Shire PLC from GBX 5,250 ($68.53) to GBX 5,200 ($67.88) and set a  hold rating for the company in a report on Wednesday, September 28th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of GBX 5,828 ($76.07).

Analyst Recommendations for Shire PLC (LON:SHP)

Shares of Shire PLC (LON:SHP) traded up 2.44% on Friday, reaching GBX 5323.00. 1,457,073 shares of the company’s stock were exchanged. The firm’s market capitalization is GBX 36.35 billion. The firm has a 50 day moving average of GBX 4,985.70 and a 200 day moving average of GBX 4,560.67. Shire PLC has a one year low of GBX 2,707.19 and a one year high of GBX 5,377.00.

The business also recently declared a dividend, which was paid on Friday, October 7th. Stockholders of record on Thursday, September 8th were paid a dividend of GBX 3.51 ($0.05) per share. The ex-dividend date of this dividend was Thursday, September 8th. This represents a dividend yield of 0.07%.

In related news, insider Dominic Blakemore purchased 133 shares of the stock in a transaction dated Friday, September 30th. The shares were acquired at an average cost of GBX 5,010 ($65.40) per share, with a total value of £6,663.30 ($8,697.69).

Shire PLC Company Profile

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with's FREE daily email newsletter.